在严重的先天性V因子缺乏症中,抑制剂的发展
Clara Guilbault1, Arnaud Bonnefoy2, Georges-Étienne Rivard3
1Faculty of Medicine, Université Laval.
Journal of pediatric hematology/oncology
|August 11, 2025
概括
一个患有严重先天性V因子 (FV) 缺乏症的年轻女孩在治疗后产生了抑制剂抗体. 成功治疗涉及复合因子VIIa,FFP和免疫抑制,消除抑制剂.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 儿科 儿科 儿科
背景情况:
- 严重的先天性V因子 (FV) 缺乏症是一种罕见的出血障碍.
- 获得的对凝血因子的抑制剂,包括FV,可以使管理复杂化.
- 发育FV抑制剂可以导致耐火性出血发作.
研究的目的:
- 在患有先天性FV缺陷的儿科患者中描述一种获得的抗FV抑制剂病例.
- 报告抗病毒抑制剂的管理和成功根除.
- 评估免疫耐受性诱导和免疫抑制疗法的疗效.
主要方法:
- 诊断严重的先天性FV缺陷.
- 在新鲜冷血 (FFP) 输血后开发抗FV抑制剂.
- 使用ELISA证实了抑制剂的存在.
- 使用复合因子VIIa (rFVIIa) 控制出血.
- 用FFP和免疫抑制疗法启动免疫耐受性诱导.
主要成果:
- 患者开发了一个高位的抗FV抑制剂.
- 使用rFVIIa.a有效控制出血情况.
- 治疗一年后,FV抑制剂水平变得无法检测.
- 患者取得了良好的临床结果,没有进一步的出血.
结论:
- 获得的FV抑制剂可以在患有先天FV缺乏症的患者中发展.
- 结合FFP,rFVIIa和免疫抑制疗法,可以成功消除FV抑制剂.
- 免疫耐受性诱导协议是有效的管理获得因子抑制剂.
相关概念视频
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
903
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
903
Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Enzyme Inhibition
79.5K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
79.5K


